Manning & Napier Group LLC raised its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 182,669 shares of the medical research company’s stock after buying an additional 161 shares during the quarter. Manning & Napier Group LLC’s holdings in Amgen were worth $35,347,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. increased its holdings in shares of Amgen by 3.4% in the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after purchasing an additional 1,585,911 shares in the last quarter. Morgan Stanley increased its holdings in shares of Amgen by 0.5% in the 2nd quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock worth $1,244,470,000 after purchasing an additional 34,674 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Amgen by 1,334.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock worth $910,860,000 after purchasing an additional 4,598,329 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Amgen by 5.0% in the 1st quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock worth $894,700,000 after purchasing an additional 225,485 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Amgen by 9.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock worth $512,383,000 after purchasing an additional 239,576 shares in the last quarter. Institutional investors and hedge funds own 76.24% of the company’s stock.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the completion of the sale, the director now owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. Insiders sold 17,851 shares of company stock valued at $3,671,900 in the last ninety days. 0.25% of the stock is currently owned by corporate insiders.
Shares of AMGN traded up $1.53 during trading hours on Thursday, hitting $198.22. The stock had a trading volume of 6,282 shares, compared to its average volume of 2,606,578. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90. The firm has a market capitalization of $118.24 billion, a PE ratio of 13.77, a PEG ratio of 2.56 and a beta of 1.11. The stock has a fifty day moving average price of $199.68 and a 200 day moving average price of $186.14.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the company posted $3.83 earnings per share. Amgen’s revenue was down 3.1% compared to the same quarter last year. As a group, analysts anticipate that Amgen, Inc. will post 14.31 EPS for the current fiscal year.
A number of analysts have commented on the company. Goldman Sachs Group set a $243.00 target price on Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. Piper Jaffray Companies lifted their target price on Amgen from $210.00 to $218.00 and gave the stock an “overweight” rating in a report on Monday, August 26th. Mizuho reissued a “hold” rating and issued a $212.00 target price on shares of Amgen in a report on Sunday, September 29th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Citigroup reissued a “buy” rating on shares of Amgen in a report on Monday, August 12th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and an average price target of $217.41.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.